Improving the prognosis of diabetic patients: Evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue SUPPL. 2, 2000, Pages 25-28

  Bedigian, Martin P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ABCD 2V; Angiotensin II receptor blocker; Hypertension; Nephropathy; Neuropathy; Retinopathy; Type 2 diabetes; Valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT;

COHORT ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS; HUMAN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DIABETES COMPLICATIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 0346046819     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.050     Document Type: Article

References (16)

1. Dupree EA, Meyer MB. Role of risk factors in complications of diabetes mellitus. Am J Epidemiol 1980; 12: 100-12.
2. Nelson RG, Newman JM, Knowler WC et al. Incidence of end stage renal disease in NIDDM in Pima Indians. Diabetalogia 1988; 31:730-16.
3. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease. Diabetes Care 1979; 2: 120-6.
4. Knowler WC, Bennett PH, Ballantine EJ. Increased incidence of retinopathy in diabetes with elevated blood pressure. N Engl Med 1980; 301: 645-50.
5. Maser R. Epidemiological correlates of diabetic nephropathy. Diabetes 1989; 38: 1456-61.
6. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Int Med 1997; 57: 2413-46.
7. Savage S, Johnson Nagel N, Estacio RO et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online J Curr Clin Trials: Doc No 104, 1993.
8. Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) trial. Diabetologia 1996; 39(12): 1646-54.
9. Estacio RO, Savage S, Schrier RW et al. Baseline characteristics of participants in the appropriate blood pressure control in diabetes trial. Con Clin Trials 1996; 17: 242-57.
10. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with diabetes and hypertension. N Engl Med 1998; 338: 645-52.
11. Estacio RO, Jeffers BW, Schrier RW et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes: Diabetes Care 2000; 23(Suppl 2): B54-B64.
12. Schrier RW, Estacio RO, Bedigian MP et al. Appropriate Blood Pressure Control in Diabetes - Part 2 with Valsartan (ABCD-2V trial). Am J Hypertens 1999;12(4 pt 2): 141A.
13. Bedigian MP, Estacio RO, Schrier RW et al. Baseline characteristics of the hypertensive cohort of the appropriate blood pressure control in diabetes trial - part 2 with valsartan (ABCD-2V). Am J Hypertens 2000; 13(4 part 2): 56-57A.
14. Thogersen AM, Jansson J, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 1998; 98: 2241-7.
15. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334(15): 952-7.
16. Bedigian MP, Estacio RO, Schrier RW et al. Insulin, tPA and PAI-1 levels and their correlations with cardiac risk and disease factors in the hypertensive cohort of the appropriate blood pressure control in diabetes trial-part 2 with valsartan (ABCD-2V). Am J Hypertens 2000; 13(4 part 2): 100-1A.